logo

Last Update

This profile was last updated on 5/3/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Gregory Phelps?

Gregory D. Phelps

Director of Development

RenaMed Biologics , Inc.

Direct Phone: (401) ***-**** ext. ***direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Realtor

CENTURY 21 M&M and Associates


Partner

Red Sky Partners, LLC.


Corporate Director

EPIX Pharmaceuticals , Inc.


Vice Chairman

Dyax Corp.


Executive Vice President

Genzyme Corporation


Affiliations

EPIX Medical , Inc.

Board Member


Proteon Therapeutics Inc

Chairman


SmartBrief Inc

Board Member


Feinstein Kean Healthcare

Vice Chairman, Board of Directors


FKPI.com

Vice Chairman, Board of Directors


American City Business Journals , Inc.

Board Member


Education

B.S.

Electrical Engineering

Bradley University


M.B.A.

Harvard Graduate School of Business Administration


MBA

Harvard Business School


Web References(66 Total References)


www.sec.gov

Gregory D. Phelps (1)
* Dr. Kobyzev and Mr. Phelps are not standing for re-election to the Board at the Annual Meeting. As of the date of the Annual Meeting, each of Dr. Kobyzev and Mr. Phelps will no longer be directors of the Company and will no longer serve on any committee of the Board. Gregory D. Phelps has been a member of our Board since February 2008 and has served as Chairman of the Board since July 2009. Mr. Phelps is an independent advisor to biotechnology and pharmaceutical companies. He was a founder and Partner of Red Sky Partners LLC, an advisory firm providing corporate development, product strategy and leadership support to life sciences companies, from February 2009 to February 2014. Prior to that, Mr. Phelps served as Chairman and Chief Executive Officer of RenaMed Biologics, Inc. from 2004 to 2007. Prior to that, he served as Chief Executive Officer of Ardais Corporation from 2002 to 2003, as Vice Chairman and member of the executive committee of Dyax Corporation from 1998 to 2002, as Executive Vice President and Senior Vice President of Genzyme Corporation from 1991 to 1997. Mr. Phelps has previously served as a member of the board of directors of the following companies: EPIX Pharmaceuticals Inc. from 2004 to 2009, Ostex International Inc. from 1995 to 2001, Atlantic Biopharmaceuticals (now Merrimack Pharmaceuticals Inc.) from 1998 to 2000, Neozyme II Corporation from 1992 to 1996, and Genzyme Transgenics Corporation (now rEVO Biologics Inc.) from 1993 to 1995. Mr. Phelps received a B.S. in electrical engineering from Bradley University and an M.B.A. from Harvard Business School. We believe Mr. Phelps is qualified to serve as a member of our Board because of his business and professional experience. Bohlin, Canute, Haines, Kingsley and Phelps and Drs. Birner, Freund, Kobyzev and O'Leary, other than Timothy Noyes, our President and Chief Executive Officer, has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent within the meaning of the director independence standards of the NASDAQ rules and the SEC. Gregory D. Phelps is the Chairman of the Board. The independent members of the Board periodically review the Board's leadership structure and have determined that Proteon and our stockholders are well served with this structure. Gregory D. Phelps is not standing for re-election to the Board at the Annual Meeting.


www.tvm-capital.com [cached]

Proteon Also Announces Gregory D. Phelps Appointed as Chairman of the Board
WALTHAM, MA, Nov. 23, 2009 - Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year. Proteon also announces the appointment of board member Gregory D. Phelps as Chairman of the Board of Directors. Greg's appointment to Chairman of the Board provides our team with even greater access to his wealth of strategic and operational experience at an important stage of Proteon's development." "I am very happy to assume the role as Chairman of Proteon and to take a more active role in the progress of Proteon," said Greg Phelps. Greg Phelps has more than 30 years experience in the medical products and biotechnology fields, where he has held Chief Executive Officer, Board Director and senior management positions in several companies. He is co-founder and partner of Red Sky Partners LLC, a team of experienced healthcare executives focused on new ventures in clinical development and strategic consulting in the life sciences field. Greg has previously held positions of Chairman and CEO of RenaMed Biologics, Inc., Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation, Vice President of Baxter Travenol Laboratories and as CEO of Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc. He has served on the Boards of Directors of ten public and private healthcare companies and two nonprofit organizations. Greg holds a B.S. in Electrical Engineering from Bradley University and an MBA from Harvard Business School.


www.sec.gov

The board of directors is also composed of (i) two class II directors (Elkan Gamzu and Gregory D. Phelps), whose term expires upon the election and qualification of directors at the annual meeting of stockholders to be held in 2010 and (ii) two class III directors (Frederick Frank and Ian F. Smith, CPA), whose terms expire upon the election and qualification of directors at the annual meeting of stockholders to be held in 2011.
Following the resignation of Robert J. Perez from the board of directors on February 28, 2009, the board of directors, acting pursuant to our certificate of incorporation, reclassified Gregory D. Phelps, formerly a class III director, as a class II director. Gregory D. Phelps Director Gregory D. Phelps(2)(3) Gregory D. Phelps has served as a member of our board of directors since July 2004. Mr. Phelps is an independent management consultant and is a director of Proteon Therapeutics, Inc. Mr. Phelps was previously a director of RenaMed Biologics, Inc. from April 2007 to April 2008 and was the Chairman of the Board, President and Chief Executive Officer of RenaMed From October 2004 to April 2007. From June 2004 to Table of Contents September 2004, Mr. Phelps was the Vice Chairman of RenaMed. He has previously held positions of Chief Executive Officer of Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc. He has also served as Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation and Vice President of Baxter Travenol Laboratories, Inc. (now Baxter Healthcare). Mr. Phelps holds a B.S. in Electrical Engineering from Bradley University and an MBA from Harvard Business School. The board of directors has determined that each of Frederick Frank, Michael Gilman, Ph.D., Mark Leuchtenberger, Gregory D. Phelps and Ian F. Smith, CPA, comprising five of its six members, is an independent director within the meaning of the director independence standards of The NASDAQ Stock Market, or NASDAQ.


investor.epixmed.com [cached]

Gregory D. PhelpsChairman, President and Chief Executive Officer, RenaMed Biologics, Inc.Mr. Phelps is the Chairman of the Board, President, and Chief Executive Officer of RenaMed Biologics, Inc., a biotechnology company developing therapeutic products.He has previously held positions of Chief Executive Officer of Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc.He has also served as Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation and Vice President of Baxter Travenol Laboratories, Inc. (now Baxter Healthcare).


investor.epixmed.com [cached]

Gregory D. PhelpsChairman, President and Chief Executive Officer, RenaMed Biologics, Inc.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory